Figure 1
Figure 1. a) Changes in circulating CD8+ T-cells according to Lenalidomide exposure following RIC-Allo SCT for myeloma. / b) Changes in circulating CD4+CD25+FoxP3+ T-Reg cells according to Lenalidomide exposure following RIC-Allo SCT for Myeloma

a) Changes in circulating CD8+ T-cells according to Lenalidomide exposure following RIC-Allo SCT for myeloma

b) Changes in circulating CD4+CD25+FoxP3+ T-Reg cells according to Lenalidomide exposure following RIC-Allo SCT for Myeloma

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal